Arcutis Biotherapeutics
ARQT
140 hedge funds and large institutions have $974M invested in Arcutis Biotherapeutics in 2022 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 69 increasing their positions, 27 reducing their positions, and 19 closing their positions.
8,230% more call options, than puts
Call options by funds: $11.2M | Put options by funds: $135K
156% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 27
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
9.24% more ownership
Funds ownership: 98.61% → 107.85% (+9.2%)
1% more funds holding
Funds holding: 139 → 140 (+1)
14% less capital invested
Capital invested by funds: $1.13B → $974M (-$160M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$39.7M |
| 2 |
Barclays
London,
United Kingdom
|
+$18.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$17.9M |
| 4 |
Holocene Advisors
New York
|
+$17.5M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$46.9M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$7.48M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.11M |
| 4 |
O
OrbiMed
New York
|
-$5.94M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$5.24M |
ARQT Hedge Fund Activity: Q4 2022 in Review
140 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q4 2022, worth a combined $974M — down 14% from $1.13B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ARQT positions and 19 closed out — a net gain of 2 holders — while 69 added to existing stakes and 27 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $39.7M. The largest seller was Point72 Asset Management, cutting an estimated $46.9M.
- 140 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q4 2022, up from 139 in Q3 2022.
- Funds reported $974M of Arcutis Biotherapeutics stock for Q4 2022, down 14% quarter-over-quarter.
- 21 funds opened new Arcutis Biotherapeutics positions in Q4 2022 and 19 closed out, a net change of +2 holders.
- The largest Arcutis Biotherapeutics buyer in Q4 2022 was Rubric Capital Management (New York), an estimated $39.7M added.
- The largest Arcutis Biotherapeutics seller in Q4 2022 was Point72 Asset Management, an estimated $46.9M sold.
Based on aggregated 13F filings for Q4 2022.